Novo Nordisk A/S (NVO)
Pre-Market:
| Previous Close | 125.26 |
| Open | 126.57 |
| Bid | 0.00 x 2200 |
| Ask | 0.00 x 1000 |
| Day's Range | 126.34 - 128.76 |
| 52 Week Range | 75.56 - 138.28 |
| Volume | |
| Avg. Volume | 5,036,312 |
| Market Cap | 573.906B |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 48.36 |
| EPS (TTM) | 2.66 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.37 (1.07%) |
| Ex-Dividend Date | Mar 22, 2024 |
| 1y Target Est | 144.64 |
- Reuters
About 3.6 mln Medicare beneficiaries could be eligible for Wegovy coverage, study shows
About 3.6 million overweight or obese patients with heart conditions insured under the U.S. Medicare program could be eligible for coverage of Novo Nordisk's weight-loss drug Wegovy, a study published by Kaiser Family Foundation (KFF) showed on Wednesday. Wegovy was approved by the U.S. health regulator last month for lowering the risk of stroke and heart attack in overweight or obese adults who do not have diabetes.
ZacksNovo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
GlobeNewswireNovo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 22 April 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme i
